CoChat
Sign Up
Cited by 18Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchAdvanced Biosensing Techniques and Applications

High-throughput epitope profiling of antibodies in the plasma of Alzheimer’s disease patients using random peptide microarrays

Open access
Sim, Kyu-Young, Park, Sang-Heon, Choi, Kyu Yeong, Park, Jung Eun, Lee, Jung Sup, Kim, Byeong C., Gwak, Jeonghwan, Song, Woo Keun +2 more·2019·Scientific Reports
DOI 10.1038/s41598-019-40976-xPMC PMC6418098
Open this paper in CoChat — free accountOpen PDF

Abstract

The symptoms of Alzheimer’s disease (AD), a major cause of dementia in older adults, are linked directly with neuronal cell death, which is thought to be due to aberrant neuronal inflammation. Autoantibodies formed during neuronal inflammation show excellent stability in blood; therefore, they may be convenient blood-based diagnostic markers of AD. Here, we performed microarray analysis of 29,240 unbiased random peptides to be used for comprehensive screening of AD-specific IgG and IgM antibodies in the blood. The results showed that (1) sequence-specific and isotype-specific antibodies are regulated differentially in AD, and combinations of these antibodies showing high area under the receiver operating characteristic curve values (0.862–0.961) can be used to classify AD, (2) AD-specific IgG antibodies arise from IgM antibody-secreting cells that existed before disease onset and (3) target protein profiling of the antibodies identified some AD-related proteins, some of which are involved in AD-related signalling pathways. Therefore, we propose that these epitopes may facilitate the development of biomarkers for AD diagnosis and form the basis for a mechanistic study related to AD progression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-019-40976-x

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SOS1 activates the RAS signaling pathway.

    “SOS1 activates the RAS signaling pathway, and its expression level is elevated in the blood of AD patients. 78”

    From Unraveling sex differences in Alzheimer's disease and related endophenotypes with brain proteomes (2025) · cites this paper as [78]

    The Discussion and Table 2 report increased SOS1 expression in pyramidal neurons of AD patients, not in their blood. The Discussion mentions RAS only as the renin–angiotensin signalling pathway; it does not say that SOS1 activates it or another RAS pathway. The Results identify SOS1 as a potential target of antibodies upregulated in plasma, which is not a measurement of blood SOS1 expression. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • SOS1 expression level is elevated in the blood of AD patients.

    “SOS1 activates the RAS signaling pathway, and its expression level is elevated in the blood of AD patients. 78”

    From Unraveling sex differences in Alzheimer's disease and related endophenotypes with brain proteomes (2025) · cites this paper as [78]

    The Discussion reports increased SOS1 expression in pyramidal neurons of AD patients, not in their blood. The Results identify SOS1 as a potential target of upregulated antibodies in plasma; they do not report elevated blood SOS1 expression. The cited passages also do not establish that SOS1 activates RAS signaling. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 40 · Cited by 18

Research works printed but not linked: 38

  1. [1]Alzheimer’s A 2016 Alzheimer’s disease facts and figures Alzheimers Dement 2016 12 459 509 10.1016/j.jalz.2016.03.001 27570871 · DOI · Paper page
  2. [2]Philip Scheltens KB Alzheimer’s disease The Lancet 2016 388 505 517 10.1016/S0140-6736(15)01124-1 26921134 · DOI · Paper page
  3. [3]Casey DA O’Brien J Drugs for Alzheimer’s Disease: Are They Effective? Pharmacy and Therapeutics 2010 35 208 211 20498822 PMC2873716
  4. [4]Simonsen AH Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia Alzheimers Dement 2017 13 274 284 10.1016/j.jalz.2016.09.008 28341065 · DOI · Paper page
  5. [5]Blennow K Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease Alzheimers Dement 2015 11 58 69 10.1016/j.jalz.2014.02.004 24795085 PMC4386839 · DOI
  6. [6]Shipley SM Frederick MC Filley CM Kluger BM Potential for misdiagnosis in community-acquired PET scans for dementia Neurol Clin Pract 2013 3 305 312 10.1212/CPJ.0b013e318296f2df 24195019 PMC3787114 · DOI
  7. [7]Bateman TM Advantages and disadvantages of PET and SPECT in a busy clinical practice J Nucl Cardiol 2012 19 Suppl 1 S3-11 10.1007/s12350-011-9490-9 22259006 · DOI
  8. [8]Neeti Sharma ANS Exploring Biomarkers for Alzheimer’s Disease J Clin Diagn Res 2016 10 KE01 KE06 27630867 PMC5020308
  9. [9]Wu J Li L Autoantibodies in Alzheimer’s disease: potential biomarkers, pathogenic roles, and therapeutic implications J Biomed Res 2016 30 361 372 10.7555/JBR.30.20150131 27476881 PMC5044708 · DOI · Paper page
  10. [10]Gronwall C Vas J Silverman GJ Protective Roles of Natural IgM Antibodies Front Immunol 2012 3 66 10.3389/fimmu.2012.00066 22566947 PMC3341951 · DOI
  11. [11]Casali P Schettino EW Structure and function of natural antibodies Curr Top Microbiol Immunol 1996 210 167 179 8565555
  12. [12]Levin EC Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown Brain Res 2010 1345 221 232 10.1016/j.brainres.2010.05.038 20546711 · DOI
  13. [13]DeMarshall CA Detection of Alzheimer’s disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers Alzheimers Dement (Amst) 2016 3 51 62 10.1016/j.dadm.2016.03.002 27239548 PMC4879649 · DOI
  14. [14]Loebel M Serological profiling of the EBV immune response in Chronic Fatigue Syndrome using a peptide microarray PLoS One 2017 12 e0179124 10.1371/journal.pone.0179124 28604802 PMC5467847 · DOI
  15. [15]Ruprecht K Multiple sclerosis: the elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycine-alanine repeat of Epstein-Barr nuclear antigen-1 J Neuroimmunol 2014 272 56 61 10.1016/j.jneuroim.2014.04.005 24798244 · DOI
  16. [16]Reddy MM Identification of candidate IgG biomarkers for Alzheimer’s disease via combinatorial library screening Cell 2011 144 132 142 10.1016/j.cell.2010.11.054 21215375 PMC3066439 · DOI
  17. [17]Restrepo L Stafford P Magee DM Johnston SA Application of immunosignatures to the assessment of Alzheimer’s disease Ann Neurol 2011 70 286 295 10.1002/ana.22405 21823156 · DOI
  18. [18]Restrepo L Stafford P Johnston SA Feasibility of an early Alzheimer’s disease immunosignature diagnostic test J Neuroimmunol 2013 254 154 160 10.1016/j.jneuroim.2012.09.014 23084373 · DOI
  19. [19]Chapoval AI Immunosignature: Serum Antibody Profiling for Cancer Diagnostics Asian Pac J Cancer Prev 2015 16 4833 4837 10.7314/APJCP.2015.16.12.4833 26163599 · DOI
  20. [20]Singh, S. et al. Humoral Immunity Profiling of Subjects with Myalgic Encephalomyelitis Using a Random Peptide Microarray Differentiates Cases from Controls with High Specificity and Sensitivity. Mol Neurobiol, 10.1007/s12035-016-0334-0 (2016). PMC5472503 27981498 · DOI
  21. [21]Navalkar KA Application of immunosignatures for diagnosis of valley fever Clin Vaccine Immunol 2014 21 1169 1177 10.1128/CVI.00228-14 24964807 PMC4135907 · DOI
  22. [22]Riedel BC Thompson PM Brinton RD Age, APOE and sex: Triad of risk of Alzheimer’s disease J Steroid Biochem Mol Biol 2016 160 134 147 10.1016/j.jsbmb.2016.03.012 26969397 PMC4905558 · DOI · Paper page
  23. [23]Corder EH Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease Nature Genetics 1994 7 180 10.1038/ng0694-180 7920638 · DOI · Paper page
  24. [24]Jespersen, M. C., Peters, B., Nielsen, M. & Marcatili, P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res, 10.1093/nar/gkx346 (2017). PMC5570230 28472356 · DOI
  25. [25]Swardfager W A meta-analysis of cytokines in Alzheimer’s disease Biol Psychiatry 2010 68 930 941 10.1016/j.biopsych.2010.06.012 20692646 · DOI · Paper page
  26. [26]Lambert JC Implication of the immune system in Alzheimer’s disease: evidence from genome-wide pathway analysis J Alzheimers Dis 2010 20 1107 1118 10.3233/JAD-2010-100018 20413860 · DOI · Paper page
  27. [27]Verdile G Associations between gonadotropins, testosterone and beta amyloid in men at risk of Alzheimer’s disease Mol Psychiatry 2014 19 69 75 10.1038/mp.2012.147 23089633 · DOI
  28. [28]Bowen RL Perry G Xiong C Smith MA Atwood CS A clinical study of lupron depot in the treatment of women with Alzheimer’s disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks J Alzheimers Dis 2015 44 549 560 10.3233/JAD-141626 25310993 · DOI
  29. [29]Caceres A Vargas JE Gonzalez JR APOE and MS4A6A interact with GnRH signaling in Alzheimer’s disease: Enrichment of epistatic effects Alzheimers Dement 2017 13 493 497 10.1016/j.jalz.2016.05.009 27337227 · DOI
  30. [31]Furiya Y Renin-angiotensin system blockers affect cognitive decline and serum adipocytokines in Alzheimer’s disease Alzheimers Dement 2013 9 512 518 10.1016/j.jalz.2012.06.007 23142434 · DOI
  31. [32]McShea A Zelasko DA Gerst JL Smith MA Signal transduction abnormalities in Alzheimer’s disease: evidence of a pathogenic stimuli Brain Res 1999 815 237 242 10.1016/S0006-8993(98)01135-4 9878757 · DOI
  32. [33]Nikolaev A McLaughlin T O’Leary DD Tessier-Lavigne M APP binds DR6 to trigger axon pruning and neuron death via distinct caspases Nature 2009 457 981 989 10.1038/nature07767 19225519 PMC2677572 · DOI · Paper page
  33. [34]Jung CG Beta-amyloid increases the expression level of ATBF1 responsible for death in cultured cortical neurons Mol Neurodegener 2011 6 47 10.1186/1750-1326-6-47 21729327 PMC3145572 · DOI
  34. [35]Afanador L The Ca2+ sensor S100A1 modulates neuroinflammation, histopathology and Akt activity in the PSAPP Alzheimer’s disease mouse model Cell Calcium 2014 56 68 80 10.1016/j.ceca.2014.05.002 24931125 · DOI
  35. [36]Boutillier S Sp3 and sp4 transcription factor levels are increased in brains of patients with Alzheimer’s disease Neurodegener Dis 2007 4 413 423 10.1159/000107701 17934324 · DOI
  36. [37]Hossain MS Reduction of Ether-Type Glycerophospholipids, Plasmalogens, by NF-kappaB Signal Leading to Microglial Activation J Neurosci 2017 37 4074 4092 10.1523/JNEUROSCI.3941-15.2017 28292831 PMC6596592 · DOI
  37. [38]Gautam V D’Avanzo C Hebisch M Kovacs DM Kim DY BACE1 activity regulates cell surface contactin-2 levels Mol Neurodegener 2014 9 4 10.1186/1750-1326-9-4 24405708 PMC3899608 · DOI
  38. [39]McKhann GM The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease Alzheimers Dement 2011 7 263 269 10.1016/j.jalz.2011.03.005 21514250 PMC3312024 · DOI · Paper page

Authors
Sim, K.-Y., Park, S.-H., Choi, K. Y., Park, J. E., Lee, J. S., Kim, B. C., Gwak, J., Song, W. K., Lee, K. H., & Park, S.-G.
Affiliations
  • Gwangju Institute of Science and Technology (KR)
  • Chosun University (KR)
  • Chonnam National University (KR)
  • Seoul National University (KR)
Corresponding author
  • Lee, Kun Ho
  • Park, Sung-Gyoo
ORCID
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2019-03-14
Volume
9
Issue
1
Pages
4587-4587
ISSN
2045-2322 (ISSN-L)
DOI
10.1038/s41598-019-40976-x
PMC
PMC6418098
OpenAlex
W2921947599
Cited by
18
References
40
Citations by year
2025: 5 · 2024: 1 · 2023: 3 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 1
FWCI
1.54
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
National Research Foundation of Korea (2016M3C7A1905475, 2016R1A5A1007318, 2017R1E1A1A01074299)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced Biosensing Techniques and Applications
Keywords
Alzheimer's disease, autoantibodies, IgG, IgM, blood-based biomarkers, neuronal inflammation, antibody-secreting cells, disease classification
MeSH terms
Alzheimer Disease, Epitopes, Autoantibodies, Female, Humans, Male, Peptides, ROC Curve, Signal Transduction, Biomarkers, Epitope Mapping, Computational Biology, Protein Array Analysis, High-Throughput Screening Assays

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review